Floatz logo

Loncastuximab Tesirine

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

University of California, Davisantibody_drug_conjugatePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
81/ 100

Competitive context

51 Active assets in the High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
ETOPOSIDE
University of Washington
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Loncastuximab Tesirine is also rated in:

Refractory Diffuse Large B-Cell LymphomaDormant
B
Indicative ·
62 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
B
Indicative ·
61 / 100
View asset →
Refractory B-Cell Non-Hodgkin LymphomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →